INTRODUCTION
Human autosomal dominant polycystic kidney disease (ADPKD) is one of the most common genetic diseases. ADPKD is characterized by the presence of many renal epithelial cysts in all segments of the nephron that affect both kidneys. The cystic dilatations of tubules and glomeruli in these kidneys ultimately result in the remodeling of the renal architecture and alter renal physiologic functions. Consequently, ADPKD patients develop renal insufficiency during the fifth to sixth decade of life that accounts for 10% of all individuals requiring renal replacement therapy.
Mutations in the PKD1 or PKD2 genes are associated with ADPKD. The PKD1 gene, the most frequently mutated, is large and spans 54 kb consisting of 46 exons, generates a 14 kb transcript and encodes a 4302 amino acid protein called polycystin-1 (PC1) (1 -4) . In silico, PC1 analysis revealed that the amino terminal portion consists of multimodular domains described as: leucine-rich repeats flanked by cysteine-rich structures (LRR), an LDL-A domain, a C-type lectin domain, 16 PKD (Ig-like) tandem repeats, an REJ-like domain (receptor for egg jelly), a G protein-coupled receptor proteolytic site or GPCR-autoproteolysis inducing (GPS or GAIN) (1, 3, 5, 6 ) just prior to the first transmembrane domain. These motifs are followed by 11 transmembrane domains. The first intracellular/ cytoplasmic loop contains a so-called PLAT domain (for PC1, lipoxygenase and alpha toxin) (7 -10) , whereas the last intracellular loop contains a potential PEST sequence and at the C-terminal end, a coiled-coil domain comprised of five heptad repeats. Based on these predictions, the PC1 protein could act as a cell-surface receptor or participate in a large membrane protein complex that could be involved in cell -cell and/or cell -matrix interactions. However, the role of PC1 and in particular that of the extracellular domain remains elusive.
A wide spectrum of mutations for the PKD1 gene has been reported and most of them belong to a unique family. * To whom correspondence should be addressed at: Molecular Genetics and Development, IRCM, 110 ave. des Pins ouest, Montreal, Quebec, Canada H2W 1R7. Tel: +1 5149875712; Fax: +1 5149875585; Email: trudelm@ircm.qc.ca Frequently, these PKD1 mutations are predicted to cause truncated transcripts due to frameshift, deletion, nonsense or splicing defects, although a significant minority is missense (11) (12) (13) (14) . Some of these mutated PKD1 transcripts have also been shown to produce truncated proteins (15, 16) . Notably, patients expressing both a PKD1 truncated allele and a wild-type allele developed PKD.
Although ADPKD transmission is dominant, the pathogenic mechanism leading to the disease is still not clearly established. Few groups have proposed that a PKD1 gene-dosage or -imbalance-dependent mechanism, based on amorphic/ loss-of-gene-function, hypomorphic and hypermorphic/gainof-gene-function alleles, is responsible for PKD1 pathogenesis. Evidence for recessive inactivation of PKD1 was provided by somatic mutations, in addition to an inherited germ-line mutation, found in a subset of renal cysts (17) (18) (19) . Hypomorphic alleles have also been identified in some ADPKD patients (20) . Evidence also points to a gain-of-function mechanism underlying human ADPKD pathogenesis that is supported from overexpression of the normal PKD1 allele as well as by the majority of cysts staining positively for PC1 (15, 21, 22) .
In mice, cystogenesis can result from various Pkd1 mutations. A loss-of-heterozygosity, hypomorphic allele has been shown to be associated with the formation of renal cysts (23 -30) . More recently, we have produced transgenic mice with specific renal and systemic Pkd1 overexpression that developed a cystic phenotype (31, 32) . Altogether, these results indicated that a renal imbalance in Pc1 levels could lead to PKD phenotype and suggest that a similar mechanism may prevail in human ADPKD.
To mimic a human ADPKD mutation in mice and gain insight into the role of PC1 extracellular domain in mice, we have generated a truncated form of the Pkd1 gene based on four described truncated ADPKD mutations (p130/E3020X, WS219, Y2991X, W3001X). These mutations are located between the extracellular region and the membrane junction (11, 14) , and PC1 lacks specifically both the membranespanning and intracellular domains. Using homologous recombination on our characterized Pkd1-BAC, we have engineered a truncated Pkd1 gene (Pkd1 extra ) that produces only the extracellular Pc1 domain (Pc1 extra ). Expression of this truncated Pkd1 extra transgene caused a slow, progressive, cystic phenotype associated with renal insufficiency recapitulating the development of human ADPKD.
RESULTS

Production of Pkd1 extra -BAC and transgenic mice
To investigate the pathogenic role and function of the Pc1 extracellular domain, we mimicked a truncated form of PC1 that was previously documented in ADPKD patients namely, WS219, p130/E3020X, Y2991X, W3001X (11, 12, 14, 33) . The Pkd1 gene was truncated to delete the protein region just prior to the first transmembrane and the membranespanning and intracellular domains (Fig. 1A) , using homologous recombination on the Pkd1-BAC that we have isolated and characterized (31) . The Pkd1-BAC was modified with a recombination vector that contained Pkd1 exon23 -25 gene till nucleotide 31 129 corresponding to amino acid 3043 just prior to the first transmembrane region, followed by two point mutations to create a stop codon (F3043X) and adjoined directly to the non-coding sequences of Pkd1 exon 46, poly A and flanking sequences for appropriate transcript processing (Supplementary material, Fig. S1A ). This vector served to produce the Pkd1 extra -BAC that was then analyzed for integrity with four restriction enzymes and seven probes as described for wild-type Pkd1-BAC (31) (Supplementary material Fig. S1B ). The Pkd1 extra fragment (77 kb) was isolated from the Pkd1 extra -BAC (Fig. 1A) that removed BAC vector sequences, Tsc2 regulatory elements and 5
′ half of the gene to avoid altered expression and was purified for transgenic mice production.
Four Pkd1 extra transgenic mouse lines were generated carrying multiple copies of the transgene ( 2, 12, 50, 85) . These transgenic lines were analyzed for transgene integrity by genomic DNA analysis using polymorphisms, Southern and PCR (32) . All lines showed intact flanking sequences of the 5 ′ Pkd1 extra transgene based on the presence of a polymorphism ( 4.5 kb upstream) specific to the 129/Sv strain from which the Pkd1-BAC derives compared with the C57BL/6J and CBA/J strains that served to generate transgenic mice (Fig. 1B) . The Pkd1 extra transgene integrity was demonstrated by Southern blot analysis using three restriction enzymes and five probes ( Fig. 1C and D) .
Pkd1 extra transgene expression analysis
Transcript analysis was carried out by various complementary means. First, northern blotting using a two-step agarose gel showed that Pkd1 extra kidneys from the different transgenic lines expressed a 9.76 kb specific transcript of the expected size, whereas the endogenous transcript was detected at 14.14 kb (Fig. 2A) . Among the four different transgenic lines (n ¼ 3 -5 mice per line), 2-to 80-fold renal expression levels were obtained for the Pkd1 extra transgene above the endogenous expression level. Noticeably, the Pkd1 extra transgene levels did not appear to alter the endogenous Pkd1 expression levels. Second, semi-quantitative RT -PCR was performed for the four transgenic lines at adult age and was designed to distinguish the transgenic from the endogenous transcript by using primers in exon 24 and 3 ′ UTR due to the novel 3 ′ Pkd1 extra junction (Fig. 2B) . Expression of the truncated Pkd1 extra transgene was evaluated relative to the S16 ribosomal protein gene product as internal control. Various quantities of RT aliquots were used to determine the linear range for expression analysis. The Pkd1 extra transgene was expressed in all tested tissues (kidneys, brain, liver, lung, spleen) of the four transgenic mouse lines, with the highest expression in brain and lung (Fig. 2B) . The transgene expression pattern essentially followed that of the Pkd1 endogenous gene. Third, quantitative expression analysis for total endogenous and transgene expression was carried out by real-time PCR with primers in exon1 and 2, on transcript from numerous tissues including kidneys, brain, heart, lung, spleen, liver and pancreas. As shown in Figure 2C , renal expression of total Pkd1 increased proportionally with transgene copy number. In comparison with the kidneys, total Pkd1 expression was generally higher in brain, heart and lung, whereas levels were lower in spleen, liver and pancreas.
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Pc1 extra protein expression analysis
We then monitored protein expression in the Pkd1 extra transgenic mice. We first verified by using a Tsc2 antibody against the C-terminal domain that the transgene did not alter Tsc2 protein (tuberin) expression levels since it can induce cyst formation (34 -36) . As shown in Figure 3A , Tsc2 protein levels were similar both in the lowest and highest Pkd1 extra transgenic expressors as in the controls. Significantly, no truncated Tsc2 protein was detected in the transgenic kidneys. These findings confirmed that the transgene did not modify Tsc2 expression levels. Expression of the protein from the Pkd1 extra transgene Pc1 extracellular domain (Pc1 extra ) in comparison with endogenous and full-length transgenic Pc1 controls was quantified in adult kidneys (n ¼ 5-6/transgenic line) of the four transgenic lines. Pc1 and Pc1 extra were detected by immunoblotting with the monoclonal antibody 7e12 which recognizes the extracellular LRR domain (Fig. 3B) . The protein specificity was confirmed by the presence of a strong Pc1 band in transgenic kidney extracts of Pkd1 TAG 26 mice overexpressing the native Pkd1 gene ( 15-fold) as positive control (32) . Truncated Pc1 extra protein encoded by the transgene has a predicted mass without posttranscriptional modification of 328 kDa, same as the N-terminal Pc1 GPS/GAIN domain in comparison with the 466 kDa fulllength Pc1. Levels of Pc1 extra in the kidneys increased with transgene copy numbers and RNA expression levels, indicating that this truncated protein is relatively stable (Fig. 3B) . Notably, renal expression in the Pkd1 extra 11 line displayed markedly higher levels of protein than in the Pkd1 TAG 26 line, despite having similar transgene copy numbers ( 12 versus 15 copies) (Fig. 3B) . In fact, the Pkd1 TAG 26 line had comparable levels with the 2-copy transgene of the Pkd1 extra 39 line. Interestingly, transgenic Pkd1 extra kidneys showed at a given transgene copy number, a disproportional increase in the levels of the Pc1 extra protein relative to the native Pc1. This suggests that the Pc1 extra protein is protected from degradation, more stable and/ or not secreted in comparison with the native Pc1.
To determine whether this increased expression was characteristic of the Pc1 extra protein or peculiar to expression in renal cells, extrarenal tissues were monitored for Pc1 extra and Pc1 expression in the Pkd1 extra 39 and 11 transgenic mice. Levels of Pc1 extra and Pc1 protein for extrarenal tissues followed approximately Pkd1 extra transcript levels except for the brain as previously detected in the Pkd1 TAG lines (32) . Similar to the kidneys, extrarenal tissues of the Pkd1 extra lines exhibited higher protein levels of Pc1 extra relative to Pc1 for equivalent transcript levels or transgene copy number (Fig. 3C) . The similar expression range from the Pkd1 extra 39 and Pkd1 TAG 26 lines in Figure 3C suggests that either Pc1 extra processing or stability is increased and sustained in renal as well as in extrarenal tissues. Since the Pc1/Pc1 extra band appears as a doublet in wild-type and transgenic mice and Pc1 has many glycosylation sites, we examined the glycosylation status of Pc1/Pc1 extra . Western analysis of total kidney protein extracts was performed with untreated (non-deglycosylated, ND) samples, treated with PNGase, which removes all N-linked carbohydrate groups, or treated with Endoglycosidase H (Endo H), which cleaves high mannose. To monitor Pc1/Pc1 extra within a same set of experiments, significantly less protein ( 2.5-to 25-fold) was used for Pkd1 extra kidneys relative to controls, thereby resulting mainly in the analysis of the transgenic protein. Pc1 extra or native Pc1 in Pkd1 extra , controls and Pkd1 TAG mice are heavily glycosylated as indicated by the major shift in size upon treatment with PNGase (Fig. 3D) 11 and control mice. MEF cells were grown in serum-free media and Pc1/Pc1 extra proteins monitored in the media for secretion and in the cells. From cell culture media, the exosomes and exosome-free subfractions were isolated via ultracentrifugation or Exoquick protocol. As shown in Figure 3E , Pc1/Pc1 extra proteins were present in exosomes from both non-transgenic control and Pkd1 extra 11 MEFs. In addition, exosomes from Pkd1 extra 11 MEFs displayed substantially higher levels ( 10-to 12-fold) of Pc1/Pc1 extra than the controls, consistent with Pc1 extra overexpression. In non-transgenic control and Pkd1 extra 11 media devoid of exosomes, free Pc1/ Pc1 extra protein levels seem increased ( 3-fold) in Pkd1 extra 11 relative to controls, though in decreased proportion based on total expression levels of Pkd1 extra 11 and controls (Fig. 3B ). An aliquot of MEF cells from Pkd1 extra 11 and non-transgenic controls were fractionated in cytosol and triton-soluble membrane (Fig. 3F ). Marked increase in Pc1/Pc1 extra expression (.10-fold) was detected in total MEF extracts of Pkd1 extra 11 in comparison with controls. In both the cytosol and the tritonsoluble membrane fractions, Pc1/Pc1 extra was detected in Pkd1 extra 11 as well as in controls (Fig. 3F) , correlating with the renal Pc1/Pc1 extra glycosylation analysis. ′ UTR. The highest expression was consistently observed in kidney, lung and brain for all lines. Ribosomal protein S16 served as internal control. M, 100 bp DNA ladder; Ki, kidney; Lu, lung; Br, brain; Li, liver; Sp, spleen. (C) Quantitative real-time PCR was carried out in triplicate for adult Pkd1 extra mice (n ¼ 3) of all transgenic lines. Expression analysis on the kidney, lung, brain, liver, heart, spleen and pancreas was performed using primers in exon 1 and exon 2 of the Pkd1 gene. Control kidneys were set at 1. Transgene expression analysis followed the Pkd1 endogenous expression pattern and was relatively proportional to transgene copy number.
* n ¼ 2.
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Histopathologic anomalies in Pkd1 extra mice
To evaluate progression of the cystogenic disorder in the Pkd1 extra transgenic mouse lines, we carried out non-invasive imaging by ultrasound measurements using a VisualSonics Vevo 660 Imaging System with a 40 MHz scanhead. Analysis of Pkd1 extra transgenic lines 11 and 39 (n ¼ 8) at ≥15 months showed readily detectable multiple macro-and micro-cysts ( Fig. 4A and B) .
To investigate the phenotype induced by the transgene expression, we subjected the four Pkd1 extra transgenic mouse lines (n . 16 per line; n ¼ 141) including founders and progenies to complete histologic analysis. Although our analysis was performed on various organs, anomalies were mainly confined to the kidneys. All transgenic mouse lines exhibited characteristic features of PKD, whereas non-transgenic controls did not develop these disorders. Interestingly, very mild renal tubular dilatation can be detected in 2-month-old Pkd1 extra mice. With advancing age, the renal tubular dilatation phenotype progressed similarly for both the lowest and highest Pkd1 extra -expressing lines, a key characteristic of ADPKD (Supplementary material, Fig. S2 ). Both kidneys of Pkd1 extra transgenic mice over time became pale with an embossed surface and were severely affected by macro-and micro-cysts ( Fig. 4C and D) . Glomeruli displayed prominent cysts associated with hyperplasia of the parietal epithelial cells (Fig. 4F, G and H) . The glomerular tufts were hypocellular and became sclerotic. The renal parenchyma displayed tubular cysts, but also loss of tubules as well as the presence of mild to extensive interstitial fibrosis ( Fig. 4I and J) , with localized lymphoid infiltrates often perivascular. Thus, the Pkd1 extra transgenic mice developed typical PKD manifestations that progressed akin with age in all four lines.
Because defects in tubulogenesis can occur from inhibition of Pc1 cleavage (5), ex vivo incubation of peptides against the Pkd1 extracellular domain (37) , and was recently associated with renal cysts formation (38) , we queried whether Pkd1 extra expression could alter the regulation of ureteric branching in vivo. To evaluate ureteric branching or tubulogenesis, we quantified the number of glomeruli/nephron per square millimeter from stained sections in young Pkd1 extra transgenic mice at 1.5 months of age as described (39 
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Since Pkd1 TAG mice displayed cilia anomalies prior to overt cystogenesis (32), cilia of renal epithelial cells were monitored by a-acetylated tubulin staining in Pkd1 extra and control mice. The cilia size distribution measured at micrometer interval in Pkd1 extra 39 and 2 lines at precystic age showed that most cilia (n ¼ 389) were of 2 -4 mm in length (55 -61%) similar to controls (n ¼ 428; 54%). At cystic age, cilia in Pkd1 extra 11 and 2 lines displayed no difference in cilia size distribution or structure relative to controls. These data suggest that the cilia length is not implicated in Pkd1 extra cystogenesis.
Altered renal physiologic function in Pkd1 extra transgenic mice
Mice from the Pkd1 extra transgenic lines exhibited renal functional anomalies resembling those in ADPKD compared with age-matched controls. The renal physiology was investigated by urine analysis in comparison with the severe PKD mouse model SBM (40) as well as by blood analysis (Tables 1 and  2 ). Transgenic mice displayed 3 -4-fold increase in urine volume, a concentrating defect that progressed with age (≥15 months). Consequently, renal parameters in these mice also exhibited decrease in urine osmolality, urea nitrogen, creatinine, protein and ion excretion (Table 1) . Notably, these alterations are frequent also in human ADPKD. In addition, we qualitatively analyzed the urine protein composition from the four Pkd1 extra transgenic mouse lines by SDS -PAGE. As shown in Figure 5A , transgenic mice of all lines displayed non-selective proteinuria. This abnormal protein leakage was already detectable at 12 months and increased further with age. Consistent with these altered urine parameters, the levels of serum blood urea nitrogen (BUN) and serum creatinine were elevated, indicating renal insufficiency (Table 2) . Since renal insufficiency frequently causes hematologic anomalies in both mice and humans, hematocrit was measured in all of our Pkd1 extra transgenic mouse lines. These mice showed important decrease in hematocrit levels, providing evidence for chronic renal insufficiency (Table 2 ), similar to human ADPKD pathogenesis.
To determine whether Pc1 extra in Pkd1 extra transgenic mice is present in urinary exosomes and/or free in the urine, as native Pc1 in non-transgenic and Pkd1 TAG 26 controls, we isolated urinary exosomes. Pc1/Pc1 extra was detected in exosomes of Pkd1 extra lines 2, 11 and 39 and of non-transgenic control and transgenic Pkd1 TAG 26 . In transgenic Pkd1 extra lines and Pkd1 TAG 26 mice, exosomal Pc1/Pc1 extra levels appear to increase in parallel with the range of overexpression (Fig. 5B) . In exosome-free urine, secreted Pc1/Pc1 extra was detected in transgenic Pkd1 extra and Pkd1 TAG 26 mice (Fig. 5C ). Since non-transgenic control mice had very low to barely detectable Pc1 levels, this implies that mainly Pc1 extra is the secreted form in the urine of Pkd1 extra lines. Noticeably, levels of Pc1 extra in exosome-free urine, upon comparison of total expression in Pkd1 extra lines with Pkd1 TAG 26 (Fig. 3B) , suggest that the Pc1 extra protein is not as efficiently secreted as the native Pc1.
Animals from these Pkd1 extra transgenic lines manifested late-onset of renal failure. Indeed, the mean lifespan in mice of line 2 (n ¼ 10) was 17.3 + 4.5 months of age, line 9 (n ¼ 9) 23.0 + 5. Functional analysis of Pkd1 extra mice on hemizygous Pkd1 background
In an attempt to genetically mimic the human context, the Pkd1 extra 39 line was mated to mice with a Pkd1 null allele (41) to produce compound heterozygous Pkd1 extra 39;Pkd1
mice. Histomorphologic analysis of kidneys in the doubleheterozygote adult mice (n ¼ 12; 11-23 months) was compared with Pkd1 extra 39 (n ¼ 22; 15-29 months) and Pkd1 +/2 mice (n ¼ 9; 13 -26 months). Despite some phenotype.
Identification of Pkd1 extra renal molecular targets
Since Pc1 is implicated in a large complex with Pc2 in the kidneys (44) (45) (46) (47) (48) and Pkd2 dysregulation can cause cysts Urine protein from all mice showed low-molecular-weight bands that represent the normally excreted major urinary proteins (MUPs). In addition, urine samples from mice of the four Pkd1 extra transgenic lines 2, 9, 11 and 39 showed severe spillage of an 66 kDa protein, probably albumin, indicative of proteinuria reaching levels comparable with the SBM control mouse with pronounced PKD. SBM, PKD mouse model, control for proteinuria; C, non-transgenic mice, normal control; M, protein molecular weight marker; MUPs, major urinary proteins. (B) Immunoblot of protein urinary exosomes from Pkd1 extra transgenic lines 2, 11 and 39, non-transgenic control and Pkd1 TAG 26. Pc1/Pc1 extra was analyzed on a 3-8% gel and detected using the 7e12 monoclonal antibody with both long and short exposures along with exosomal marker Alix. Protein extracts of Pc1/Pc1 extra was detected in urinary exosomes of Pkd1 extra 11 and 39 (11 mg) Pkd1 extra 2 (13 mg), non-transgenic control (11 mg) and Pkd1 TAG (13 mg) mice. Levels of Pc1/ Pc1 extra appear more abundant in the highest transgenic Pkd1 extra expressors. (C) Analysis of Pc1/Pc1 extra protein secretion in the urine. The 'exosomal-free' urinary fraction (250 mg) obtained after ultracentrifugation from Pkd1 extra transgenic lines 2, 11 and 39, non-transgenic control and Pkd1 TAG 26 were analyzed on 3-8% Tris acetate gel. Pc1/Pc1 extra was detected using the 7e12 monoclonal antibody with both long and short exposures along with internal control THP for exosome-free and negative control Alix for exosome. In exosome-free urine, non-transgenic control had low levels of Pc1/Pc1 extra , whereas higher levels were observed for Pkd1 extra and Pkd1 TAG mouse lines. Levels of secreted Pc1/Pc1 extra from Pkd1 extra exosome-free samples are much lower proportionally than in the Pkd1 TAG urine.
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Human Molecular Genetics, 2013, Vol. (Fig. 7A) . In contrast, the protein expression levels of Pc2 determined by immunoblot was increased (mean 6-to 8-fold) in pre-cystic kidneys of all four Pkd1 extra lines (n ≥ 4/line; n ¼ 18) relative to control (n ¼ 4) mice (Fig. 7B ). Similar range of Pc2 increase was observed in compound heterozygous Pkd1 extra ;Pkd1 +/2 mice (data not shown). These experiments suggest that the Pc1 extra could prevent Pc2 degradation or could modulate Pc2 protein stabilization, and thereby lead to cyst formation. Underlying these hypotheses is whether Pc1 extra can interact potentially with Pc2. To monitor this interaction, coimmunoprecipitation experiments were performed with Pc2 in Pkd1 extra mice in comparison with Pkd1 TAG and control mice (Supplementary material, Fig. S3 ). Our results show that Pc1 interacts with Pc2 in kidneys of Pkd1 TAG 26 line in higher proportion than wild-type controls, consistent with increased Pc1 expression. Intriguingly, there also seems increased interaction in kidneys of Pkd1 extra 39 mice relative to controls. Although we demonstrate the existence of a protein complex, this result does not distinguish the interaction of Pc1 extra and/or Pc1 with Pc2, but both could be possible based on cellular studies (48) . Of significance, the Pc1 extra protein at the very least does not hamper Pc1-Pc2 interaction. Overall, the analogous Pc2-enhanced expression in these Pkd1 extra transgenic lines is particularly striking and correlates with the similar slow progression and development of PKD phenotype in these mice.
Because we have previously detected increased c-myc renal expression in human ADPKD kidneys and in a PKD transgenic mouse model due to Pkd1 overexpression, we next evaluated renal c-myc expression levels in the four transgenic Pkd1 extra mouse lines. When very mild renal phenotype was observed at 2 -4 months of age, these mice had little-to-no difference in endogenous c-myc transcript expression relative to control (data not shown). However, c-myc expression increased up to 6-fold at 19-26 months of age associated with cystogenesis defects (Fig. 7C) . This result is also consistent with the increased c-myc expression detected in the Pkd2 transgenic mice (51) . 80-fold increase in transcript and protein expression of the Pkd1 extracellular domain reproducibly developed late renal morphologic alterations typical of the human ADPKD. Renal insufficiency is apparent at late age and mice die of renal failure. The Pc2 overexpression in the precystic Pkd1 extra transgenic mice, a known PKD pathogenic mechanism, correlated with the comparable phenotype and revealed a potential novel regulatory crosstalk between Pc1 extra and Pc2. Our results also indicate that the cystogenic mechanism responsible for the Pkd1 extra phenotype is associated with the activation of c-myc signaling. The gradual recruitment of cysts with clinical progression makes this human-like Pkd1 extra mouse mutant a relevant model of ADPKD pathophysiology.
The design of our truncated Pc1, Pc1 extra , homologous to characterized human ADPKD mutations, corresponds to the encoded form documented in four patients with different truncated mutations at the extracellular domain/membrane junction or in the proximity of the natural GPS/GAIN cleavage site (11, 14) . This Pc1 extra mutant form devoid of the membrane-spanning and intracellular regions should be normally glycosylated, maintain its structural conformation/ folding, potentially tethered to the membrane and/or secreted, based on previous truncated receptor analysis (5, (52) (53) (54) (55) . Consequently, we have addressed the role of Pc1 extra function within the Pkd1 systemic regulation. The four different Pkd1 extra transgenic founder mice and lines expressed the transgene in a copy-dependent manner. The expression pattern of the Pkd1 extra transgene in various tissues generally paralleled that of the endogenous Pkd1 gene, although for slightly lower levels in the brain as observed in Pkd1 full-length transgenic mice (32) . This pattern suggests that the flanking regions of the Pkd1 extra transgene contain most of the necessary regulatory elements for proper expression and regulation. Of interest, expression of the Pkd1 extra transgene at 2 -80-fold that of endogenous did not affect the transcriptional regulation of the endogenous Pkd1 gene, consistent with no autoregulatory feedback as suggested (46) . The Pkd1 extra transgenic mouse lines in the presence of the endogenous gene had complete penetrance of the phenotype and shared several physiopathologic features with ADPKD. These include the development of cysts in the cortex, medulla and glomeruli, together with epithelial hyperplasia, interstitial fibrosis and focal interstitial inflammation. In parallel, alterations in renal function progressed with time, and at mid-age, Pkd1 extra mice had signs of renal insufficiency. Since the PKD phenotype was consistently observed in all four different transgenic mouse lines and the transgene integration into the mouse genome is a random phenomenon, the phenotype cannot simply be a consequence of chromosomal position effect but results from Pkd1 extra expression. Moreover, we showed that Pkd1 extra cystogenesis does not occur from an indirect role that targets a stage in the process of ciliogenesis or of ureteric branching during development. Hence, our results provide clear evidence that overexpression of the mutated Pkd1 transgene, Pkd1 extra , can produce multiple renal cysts. These Pkd1 extra mice are the most valuable orthologous mouse models generated by mimicking natural, pathologically relevant, mutations of the human PKD1 gene that can also recapitulate the slow progression of PKD.
Noticeably, the protein levels of Pc1 extra in the kidneys correlated with the Pkd1 extra transcript levels, indicating that a stable truncated Pc1 extra protein was produced and reached substantial expression levels in some lines. The cellular levels of Pc1 extra were, however, in considerable excess relative to native Pc1 for similar transcript levels. The higher levels of Pc1 extra protein than expected in comparison with native Pc1 suggested at least two explanations that are not mutually exclusive. The first is that Pc1 extra is protected from degradation, potentially from the loss of the PEST motif localized in the truncated intracellular domain. The second possibility is that Pc1 extra is not efficiently secreted and/or excreted from . Transcript expression of Pkd2 was analyzed by northern blot using a 2.2 kb cDNA murine probe. Levels of Pkd2 expression appeared unaltered in transgenic relative to control renal tissues of comparable age. Expression of Gapdh served as internal loading control. Ctrl, nontransgenic mice from same genetic background. (B) Protein expression analysis of Pc2 was carried out by western blot using the YCC2 antibody on kidneys of precystic Pkd1 extra transgenic mice and controls (1 -7 months). All Pkd1 extra transgenic mouse lines showed increased Pc2 expression in renal tissues relative to control. Actin served as internal loading control. Ctrl, non-transgenic mice from same genetic background. (C) Expression analysis of c-myc in Pkd1 extra transgenic mice. Expression levels of c-myc were analyzed by northern blot in kidneys of 19-26-month-old Pkd1 extra transgenic mice (n ¼ 2). Transcript levels of c-myc were increased up to 6.3-fold above renal control RNA. Ctrl, non-transgenic mice of same genetic background used as control; SBM, transgenic mice overexpressing c-myc used as positive control. 1 and 2, different mice from the same mouse line; rpL32, ribosomal protein L32, which served as loading control.
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Human Molecular Genetics, 2013, Vol. 22, No. 12 renal epithelial exosomes in contrast to the native Pc1 (32) . This latter mechanism is consistent with the lower levels of secreted Pc1 extra relative to the native Pc1 in urine and MEF cells and correlated with the apparent delay in Pc1 extra posttranslational maturation determined by glycolysation status. These results correlated with cell studies that expressed an analogous truncated human PKD1 due to premature termination codon at p130/E3020X and showed a small amount of PC1 extracellular domain secreted in media, whereas most remained tethered or intracellular (5) . Furthermore, we show that the difference in levels of secreted Pc1 extra relative to native Pc1 in urine and MEF cells occurred independently of Tsc2 dysregulation previously associated with mislocalization of Pc1 (56) . Nevertheless, Pc1 extra , like some truncated receptors, appears to proceed via the typical secretory pathway, as it is heavily glycosylated, excreted in exosomes and secreted. In fact, a considerable amount of Pc1 extra was excreted in exosomes and freely secreted, which may interfere with the normal Pc1 extracellular function (57) . In addition, altered Pc1 extra protein distribution may be pathogenic by not localizing to a site of functional task.
Few hypothetical mechanisms for Pkd1 extra cystogenesis may prevail. One plausible mechanism is that the Pc1 extra protein virtually indistinguishable from the naturally cleaved GPS/GAIN-Pc1 may interfere with the native Pc1 autoproteolytic cleavage and/or alter Pc1 downstream signaling. Alternatively, one mechanism may be attributed to the imbalance between the cleaved Pc1 extracellular domain and the transmembrane and intracellular domains. A dynamic interaction between the extra-and intra-cellular domains may require tight regulation to transmit changes from the microenvironment through channel activity or signaling pathways. Nonetheless, an intriguing finding is that expression of the Pkd1 extra transgene in the kidneys at various RNA or protein levels leads to similar progression and severity of the phenotype. This result indicates that Pc1 extra could be sufficient to produce the phenotype but may be limited by the availability of ligands, interacting partners and/or downstream targets and therefore the disruptive signal cannot be increased further in a dose-dependent mechanism as reported for the Pkd1 fulllength transgenic mice (32) . Moreover, the onset and phenotypic progression of PKD in the Pkd1 extra mice are milder than in the Pkd1 full-length transgenic mice. Consequently, this raises the question of Pkd1 extra pathogenetic mechanism(s) triggered in these mice in comparison with the Pkd1-overexpressing mice.
Insights into these Pkd1 extra potential pathogenic mechanism(s) were provided by analysis of renal Pc1-interacting partner Pc2. Although no difference in Pc2 expression was noted in the Pkd1 2/2 and Pkd1 +/2 embryos (29), all four Pkd1 extra transgenic lines displayed increased Pc2 expression which argues for a Pc1 extra -specific effect. Interestingly, the significantly enhanced Pc2 expression occurred despite similar Pkd2 transcript levels and indicates that Pc1 extra may modulate Pc2 protein levels directly or indirectly through a post-transcriptional mechanism. This response may result from a compensatory mechanism, reduced Pc2 protein secretion and/or decreased Pc2 degradation mechanism. Of importance, the remarkably similar range of Pc2 elevated levels correlated with the comparable PKD developmental progression in these Pkd1 extra transgenic lines. Compelling support for this interrelation is provided from the Pc2-overexpressing transgenic mice that developed very similar onset and progression of renal PKD phenotype (50) . These correlations extend to the absence of liver or pancreatic anomalies in Pkd1 extra mice as observed in transgenic Pkd2 mice (51) . Such results, combined with the observation that Pkd1 expression in cells was able to modulate the localization and perhaps the function of Pc2 (47) , suggest that Pkd1 extra pathogenic mechanism may be triggered by the dysregulation of Pc2 that in turn control cystogenic threshold.
Both Pc1 and Pc2 form complexes with many signaling molecules, hence abnormally high Pc1 or Pc2 levels likely disrupt downstream signaling. Consistent with this rationale, Pkd2 transgenic mice revealed stimulation of c-myc expression (51), one of the major mediator of cystogenesis in both humans and mice (21, 40) . Likewise, c-myc expression was also elevated in Pkd1 extra kidneys (herein) as well as in kidneys of Pkd1-overexpressing transgenic mice (31, 32) . These data indicate that Pc1 extra directly and/or via Pc2 can modulate a downstream signaling pathway that causes dysregulation of c-myc.
From the Pkd1 extra mice analyses, it is plausible that the interactions of the expressed mutant Pc1 extra promote Pc2 expression. Activation of such crosstalk regulation provides evidence for a novel cystogenic mechanism. These findings suggest that other truncated PC1 mutants may also trigger this pathogenic crosstalk. Together with previous human and mouse studies on PKD mutational mechanism, this cystogenic crosstalk mechanism is not only consistent, but also substantiates a dosage-dependent mechanism for ADPKD.
In conclusion, the Pkd1 extra mice constitute the first Pc1 extracellular mutant that can reproduce the clinical renal phenotype progression of human ADPKD disease. This model has established the basis for future studies to dissect the functions of the multimodular Pkd1 extracellular domain. Most importantly, our results provide major insights into a novel PKD pathogenic mechanism implicating a regulatory crosstalk between a truncated Pc1 mutant and Pc2. This model will be invaluable for the characterization of multiple facets of Pkd1 pathophysiology and devise innovative therapeutic strategies.
MATERIALS AND METHODS
DNA constructs and homologous recombination in Pkd1 extra -BAC
List of all primers used is provided in Supplementary Material, Table S1 .
We have previously isolated a murine Pkd1-BAC derived from a murine 129/Sv library that contained 129 kb insert with the entire Pkd1 gene (31) 
Production and genotyping of transgenic mice
The new Pkd1 extra -BAC was digested to isolate the Pkd1 extra gene away from the murine Tsc2 gene and the BAC vector sequences with MluI, a unique site 24.8 kb upstream of Pkd1 initiation codon and ClaI site 21.6 kb downstream of Pkd1 stop codon. The 77 kb Pkd1 extra fragment was isolated and purified for micro-injection into fertilized (C57BL/ 6JXCBA/J)F2 mouse eggs as described previously (40) .
Transgenic mice were analyzed for transgene integrity. The 5 ′ upstream sequence was monitored by a polymorphic sequence located in the murine Pkd1 gene at 4.47 kb upstream of the ATG translation initiation codon. A PCR protocol was designed to distinguish the 129/Sv of the Pkd1-BAC from the C57BL/6J and CBA/J inbred strains that served to produce transgenic mice (32) . The integrity of Pkd1 extra transgene sequences was monitored by signal intensity from Southern blot of genomic DNA digested with EcoRI and hybridized with six genomic probes: exon 1, exons 2 -3, exons 7 -15, exons 15-20, exons 25-34, exon 46. To verify transgene integrity in the 3 ′ downstream sequences, genomic DNA from founder mice and progenies of the four transgenic mouse lines were analyzed by Southern blot. Three restriction enzymes [EcoRI, BamHI and HindIII (Invitrogen)] that distinguished the endogenous Pkd1 gene from the Pkd1 extra transgene were used with the exons 23 -25 Pkd1 genomic probe.
Renal function analysis
BUN, creatinine, urinary proteins and osmolality levels were determined from the urine of transgenic (n . 3/line) and nontransgenic age-matched control mice (n . 4). For urine analysis, 350 -500 ml was collected per mouse. BUN and creatinine were measured with a CX9 Beckmann apparatus, whereas osmolality was evaluated with a radiometer. Qualitative assessment of urinary proteins was also performed with 50 mg of proteins on 8% SDS -PAGE as described (59) and stained with Coomassie Blue. Blood serum from transgenic and control mice was also analyzed for BUN and creatinine levels.
Histopathologic analysis
Transgenic and non-transgenic age-matched control mice were sacrificed and tissues of the kidney, lung, liver, brain, spleen, heart and pancreas readily removed. Tissues were immediately placed in formalin or paraformaldehyde and following fixation were embedded in paraffin. Five-micrometer-thick sections were stained with hematoxylin and eosin (H&E) for morphologic evaluation. Fibrosis analysis was carried out on both kidneys of transgenic and age-matched control mice (n ¼ 4-5 mice/line). Five micrometer sections were stained with Sirius red to evaluate fibrosis. Levels of renal fibrosis were quantified in function of square micrometer with a 10× objective from four cortical fields of each kidney using the Northern Eclipse software.
RNA expression analysis
Total RNA from transgenic and age-matched control tissues including kidneys, brain, lung, spleen, heart, liver and pancreas was extracted using the guanidium thiocyanate or TRIzol/ chloroform method (60) . RNA integrity was verified by electrophoresis on formaldehyde-agarose gel (61) . Expression of the Pkd1 extra transgene was analyzed by both semi-quantitative RT-PCR and real-time PCR approaches. Each pair of primers was designed such that only spliced mRNA would produce the predicted amplification products of 290, 94 and 103 bp for Pkd1 extra , Pkd1 total (endogenous and transgene) and S16, respectively. For semi-quantitative PCR, control reactions were first performed using a wide range of RT aliquots to test for linearity amplification. PCR reactions were carried out for both Pkd1 extra and S16 internal control, were run on 10% polyacrylamide gel (PAGE)/TBE1X gel and visualized by ethidium bromide staining. The image Quant 5.0 software was used for the semi-quantitative evaluation. For real-time PCR, all reactions were carried out in triplicate in a Quanti Tech SYBR Green PCR master mix (Qiagen and Quanta) using Mx4000/ 3005 multiplex PCR apparatus (Stratagene).
Expression analyses of Pkd1 extra transgene and Pkd1 endogenous gene were monitored by Northern blotting. Total kidney RNA from adult transgenic and non-transgenic mice of approximately same age (30 mg) was DNAse-digested and separated by electrophoresis on a two-step 0.8%/1.5% formaldehyde-agarose gel and transferred to nylon membranes (Osmonics, Inc.) and was hybridized with a Pkd1 exon 15-20 cDNA probe (1.55 kb) for transgene, Pkd1 exon36 -45 cDNA probe (1.6kb) for endogenous Pkd1 and a Gapdh cDNA probe for internal control (1.2 kb) as previously described (62) . Pkd2 expression analysis was performed by Northern blotting and evaluated by hybridization with a Pkd2 cDNA probe (2.2 kb) (generous gift from Dr S. Somlo) and Gapdh as control. Expression analysis of c-myc in Pkd1 extra mice was evaluated by Northern blot analysis as described for Pkd2. RNA (20 mg) was hybridized with a c-myc probe consisting of exons 2 and 3 and the ribosomal protein L32 (rpL32), which served as loading control. Both scanned films and phosphoimager were quantified by with the Image Quant 5.0 software. (41) . Gapdh (Abcam), b-tubulin and b-actin (Sigma) served as loading controls. MEF cells were isolated from Pkd1 extra transgenic and nontransgenic embryos (e14.5) and incubated for 2 -3 days with FBS until confluency. MEF cells were replated in serum-free media for 3 days to analyze free-secreted Pc1 in the media and Pc1 in exosomes. Both Exoquick protocol TM (System Biosciences, Medicorp) for exosomes as described by the manufacturer and ultracentrifugation for exosomal and exosomal-free fractions were carried out as described in Kurbegovic et al. (32) . PBS-washed MEF cells were centrifuged at 100 000g, supernatant fraction (cytosolic) was collected and the insoluble pellet resuspended and incubated in lysis buffer containing 1% Triton (Triton-soluble fraction, membrane). Proteins were analyzed on 3 -8% Tris acetate gel (NuPAGE, Invitrogen), and as controls for exosomes, the Alix/aAIP1 mouse monoclonal antibody (BD Transduction Laboratories) was used. Urinary protein from exosomes was obtained from 600-650 ml of pooled adult urine and precipitated with Exoquick protocol TM and processed as MEF cells. Similarly, exosomal and exosomal-free fractions (250 mg) were isolated by ultracentrifugation and processed as above and with sheep anti-THP antibody (Abcam).
Coimmunoprecipitation analysis was performed on adult kidney samples (600 mg) incubated with 2 mg of the monoclonal anti-rat Pc2 antibody, generously provided by Alabama University PKD core facility and with Protein A/G Plus-Agarose beads (SantaCruz Biotechnology). The material was analyzed on 4 -12% Bis-Tris (Invitrogen); controls consist of non-specific binding to the beads alone (2) without the Pc2 antibody.
